National Cancer Institute; Notice of Closed Meetings, 8082 [2016-03124]

Download as PDF 8082 Federal Register / Vol. 81, No. 31 / Wednesday, February 17, 2016 / Notices (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS) Dated: February 10, 2016. Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2016–03121 Filed 2–16–16; 8:45 am] BILLING CODE 4140–01–P Dated: February 10, 2016. Melanie J. Gray, Program Analyst, Office of Federal Advisory Committee Policy. DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2016–03124 Filed 2–16–16; 8:45 am] National Institutes of Health BILLING CODE 4140–01–P National Cancer Institute; Notice of Closed Meetings asabaliauskas on DSK5VPTVN1PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel; Omnibus SEP–12. Date: March 15, 2016. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Residence Inn Bethesda, Downtown, 7335 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Timothy C. Meeker, MD, Ph.D., Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W624, Rockville, MD 20850, 240– 276–6464 meekert@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; Planning Grants for Global Research Infrastructure in Non-Communicable Disease. Date: April 27–28, 2016. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Marriott Courtyard Gaithersburg Washingtonian Center, 204 Boardwalk Place, Gaithersburg, MD 20878. Contact Person: Michael B. Small, Ph.D., Chief, Program & Review Extramural Staff Training Office, Division of Extramural Activities, National Cancer Institute, NIH, VerDate Sep<11>2014 19:05 Feb 16, 2016 Jkt 238001 9609 Medical Center Drive, Room 7W412, Bethesda, MD 20892–9750, 240–276–6438 smallm@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: Development of In Vitro Diagnostics for the Detection of Diseases or Pathogenic Agents National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7(a)(1)(i), that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), at the National Institutes of Health, Department of Health and Human Services, is contemplating the grant to Altra Tech, Ltd. (‘‘AltraTech’’), a company incorporated under the laws of the Ireland, having an office in Shannon, Ireland, an exclusive patent commercialization license to practice the following inventions embodied in the following patent applications: US Provisional Patent Application No.60/ 846,354, entitled, ‘‘(S,S)-trans-1,2cyclopentane Diamine-modified and Gamma-lysine-modified Peptide Nucleic Acids as Probes for Nucleic Acid Detection: Synthesis and Applications,’’ filed 22 Sep 2006 [HHS Ref No. E–308–2006/0–US–01]; US Provisional Patent Application No. 60/ 896,667, entitled, ‘‘Synthesis of Transtert-butyl-2aminocyclopentylcarbamate,’’ filed 23 Mar 2007 [HHS Ref No. E–308–2006/1– US–01]; International Application PCT/ US2007/020466, entitled, ‘‘Synthesis of Trans-tert-butyl-2aminocyclopentylcarbamate,’’ filed 21 Sep 2007 [HHS Ref No. E–308–2006/2– SUMMARY: PO 00000 Frm 00049 Fmt 4703 Sfmt 4703 PCT–01]; US Patent Application No. 12/ 441,925, filed 21 Sep 2007, [HHS Ref No. E–308–2006/2–US–02]; US Patent Application No. 12/409,159, entitled, ‘‘Cross-Coupled Peptide Nucleic Acids for Detection of Nucleic Acids of Pathogens,’’ filed 23 Mar 2009 [HHS Ref No. E–308–2006/3–US–01]; US Patent No. 9,156,778, entitled, ‘‘Cross-Coupled Peptide Nucleic Acids for Detection of Nucleic Acids of Pathogens,’’ issued 13 Oct 2015 [HHS Ref No. E–308–2006/3– US–02]; US Provisional Patent Application No. 61/684,354, entitled, Cyclopentane-peptide Nucleic Acids for Qualitative and Quantitative Detection of Nucleic Acids,’’ filed 17 Aug 2012 [HHS Ref No. E–260–2012/0–US–01]; International Application PCT/US2013/ 055252, filed 16 Aug 2013 [HHS Ref No. E–260–2012/0–PCT–02]; European Patent Application No. 13753962.3, filed 11 Feb 2015, [HHS Ref No E–260– 2012/0–EP–03]; Korea Patent Application No. 10–2015–7006286, filed 11 Mar 2015, [HHS Ref No E–260–2012/ 0–KR–04]; US Patent Application No. 14/421,732, filed 13 Feb 2015, [HHS Ref No E–260–2012/0–US–05]; US Provisional Patent Application No. 61/ 333,442, filed 11 May 2010, [HHS Ref No E–129–2010/0–US–01]; International Patent Application No. PCT/US2011/ 036090, filed 11 May 2011, [HHS Ref No. E–129–2010/0–PCT–02]; European Patent Application No. 11721899.0, filed 11 May 2011, [HHS Ref No. E–129– 2010/0–EP–03]; and US Patent Application No. 13/697,123, filed 9 Nov 2012, [HHS Ref No. E–129–2010/0–US– 04]. The patent rights in these inventions have been assigned to the United States of America. AltraTech is seeking a worldwide territory for this license. The field of use may be limited to exclusive use of the licensed patent rights limited to the development and sale of transcyclopentane-modified peptide nucleic acids (PNA) in a diagnostic test system incorporating AltraTech’s proprietary sample preparation and AltraTech’s proprietary semiconductor sensor technology for the detection of infectious diseases or pathogenic agents including viruses and microorganisms. DATES: Only written comments or applications for a license (or both) which are received by the Technology Advancement Office, NIDDK, on or before March 3, 2016 will be considered. ADDRESSES: Requests for copies of the patent application, patents, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: Patrick McCue, Ph.D., Senior Licensing and Patenting E:\FR\FM\17FEN1.SGM 17FEN1

Agencies

[Federal Register Volume 81, Number 31 (Wednesday, February 17, 2016)]
[Notices]
[Page 8082]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-03124]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; Omnibus SEP-12.
    Date: March 15, 2016.
    Time: 8:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Residence Inn Bethesda, Downtown, 7335 Wisconsin Avenue, 
Bethesda, MD 20814.
    Contact Person: Timothy C. Meeker, MD, Ph.D., Scientific Review 
Officer, Resources and Training Review Branch, Division of 
Extramural Activities, National Cancer Institute, NIH, 9609 Medical 
Center Drive, Room 7W624, Rockville, MD 20850, 240-276-6464 
meekert@mail.nih.gov.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; Planning Grants for Global Research Infrastructure in Non-
Communicable Disease.
    Date: April 27-28, 2016.
    Time: 8:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Marriott Courtyard Gaithersburg Washingtonian Center, 204 
Boardwalk Place, Gaithersburg, MD 20878.
    Contact Person: Michael B. Small, Ph.D., Chief, Program & Review 
Extramural Staff Training Office, Division of Extramural Activities, 
National Cancer Institute, NIH, 9609 Medical Center Drive, Room 
7W412, Bethesda, MD 20892-9750, 240-276-6438 smallm@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: February 10, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-03124 Filed 2-16-16; 8:45 am]
 BILLING CODE 4140-01-P